Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Pertesi M; Vallée M; Wei X; Revuelta MV; Galia P; Demangel D; Oliver J; Foll M; Chen S; Perrial E; Garderet L; Corre J; Leleu X; Boyle EM; Decaux O; Rodon P; Kolb B; Slama B; Mineur P; Voog E; Le Bris C; Fontan J; Maigre M; Beaumont M; Azais I; Sobol H; Vignon M; Royer B; Perrot A; Fuzibet JG; Dorvaux V; Anglaret B; Cony-Makhoul P; Berthou C; Desquesnes F; Pegourie B; Leyvraz S; Mosser L; Frenkiel N; Augeul-Meunier K; Leduc I; Leyronnas C; Voillat L; Casassus P; Mathiot C; Cheron N; Paubelle E; Moreau P; Bignon YJ; Joly B; Bourquard P; Caillot D; Naman H; Rigaudeau S; Marit G; Macro M; Lambrecht I; Cliquennois M; Vincent L; Helias P; Avet-Loiseau H; Moreno V; Reis RM; Varkonyi J; Kruszewski M; Vangsted AJ; Jurczyszyn A; Zaucha JM; Sainz J; Krawczyk-Kulis M; Wątek M; Pelosini M; Iskierka-Jażdżewska E; Grząśko N; Martinez-Lopez J; Jerez A; Campa D; Buda G; Lesueur F; Dudziński M; García-Sanz R; Nagler A; Rymko M; Jamroziak K; Butrym A; Canzian F; Obazee O; Nilsson B; Klein RJ; Lipkin SM; McKay JD; Dumontet C

doi:10.1038/s41375-019-0452-6

Back

Journal article

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Pertesi M Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.
Vallée M Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.
Wei X Biological Statistics and Computational Biology, Cornell University, Ithaca, NY, USA.
Revuelta MV Medicine, Weill Cornell Medical College, New York, NY, USA.
Galia P ProfilExpert, Lyon, France.
Demangel D ProfilExpert, Lyon, France.
Oliver J Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.
Foll M Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.
Chen S Biological Statistics and Computational Biology, Cornell University, Ithaca, NY, USA.
Perrial E INSERM 1052, CNRS 5286, CRCL, Lyon, France.
Garderet L INSERM, UMR_S 938, Paris, France.
Corre J IUC-Oncopole and CRCT INSERM U1037, Toulouse, France.
Leleu X Inserm CIC 1402 & Service d'Hématologie et Thérapie Cellulaire, CHU La Miletrie, Poitiers, France.
Boyle EM Hôpital Claude Huriez, CHRU, Lille, France.
Decaux O Service de Medecine Interne, CHU Rennes, Rennes, France.
Rodon P Unite d'Hematologie et d'Oncologie, Centre Hospitalier, Perigueux, France.
Kolb B Hematologie Clinique, CHU de Reims, Reims, France.
Slama B Service d'Onco hematologie, CH Avignon, Avignon, France.
Mineur P Hematologie et pathologies de la coagulation, Grand Hôpital de Charleroi, Charleroi, Belgium.
Voog E Centre Jean Bernard, Institut Inter-regional de Cancerologie, Le Mans, France.
Le Bris C Service post urgences, CHU de FORT DE FRANCE, pôle RASSUR, Martinique, France.
Fontan J Hopital Jean Minjoz, CHRU Besançon, Besançon, France.
Maigre M Service d'Hemato-Oncologie, CHU Chartres, Chartres, France.
Beaumont M Hematologie clinique et therapie cellulaire, CHU Amiens, Amiens, France.
Azais I Service de rhumatologie, CHU Poitiers, Poitiers, France.
Sobol H Cancer Genetics Department, Paoli-Calmettes Institute, Aix-Marseille University, Marseille, France.
Vignon M Service d'Immuno-hematologie, Hôpital Saint Louis, Paris, France.
Royer B Service d'Immuno-hematologie, Hôpital Saint Louis, Paris, France.
Perrot A Service d'Hematologie, CHU de Nancy, Universite de Lorraine, Vandoeuvre les Nancy, Nancy, France.
Fuzibet JG Internal Medicine Department, Archet Hospital, CHU Nice, Nice, France.
Dorvaux V Service d'Hematologie, CHR Mercy, Metz, France.
Anglaret B Unite d'Hematologie, CH Valence, Valence, France.
Cony-Makhoul P Service d'Hematologie, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France.
Berthou C Service d'Hematologie, CHU de Brest, Brest, France.
Desquesnes F Haematology Department, CHU UCL Namur, Yvoir, Belgium.
Pegourie B Hematologie clinique, CHU de Grenoble, La Tronche, France.
Leyvraz S Departement d'oncologie, CHUV, Lausanne, Switzerland.
Mosser L Unite d'oncologie medicale, Pôle medical 2, Hôpital Jacques Puel, Rodez, France.
Frenkiel N CH Poissy, Saint-Germain-en-Laye, France.
Augeul-Meunier K Service Hematologie, Institut de Cancerologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.
Leduc I Hematologie, CHG Abbeville, Abbeville, France.
Leyronnas C Institut Daniel Hollard, Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France.
Voillat L Service hemato/oncologie, CH William Morey, Chalon sur Saône, France.
Casassus P Hematologie clinique, Hôpital Avicenne, Bobigny, France.
Mathiot C Intergroupe Francophone du Myelome (IFM), Bobigny, France.
Cheron N Service Hematologie, CH Bligny, Briis-sous-Forges, France.
Paubelle E Service Hematologie, CH Lyon Sud, Pierre Benite, France.
Moreau P Service Hematologie, CHU Nantes, Nantes, France.
Bignon YJ Laboratoire de Biologie Medicale OncoGènAuvergne; Departement d'oncogenetique, UMR INSERM 1240, Centre Jean Perrin, Clermont-Ferrand, France.
Joly B Service d'hematologie clinique, Pôle medecine de specialite, Centre Hospitalier Sud Francilien (CHSF), Corbeil-Essonnes, France.
Bourquard P Hematologie Clinique, CHU Nîmes, Nîmes, France.
Caillot D Hematologie Clinique, CHU Dijon, Dijon, France.
Naman H Hematologie - Oncologie medicale, Centre Azureen de Cancerologie, Mougins, France.
Rigaudeau S Service d'Hematologie et d'Oncologie, CHU de Versailles, Le Chesnay, France.
Marit G INSERM U1035, Universite de Bordeaux, Bordeaux, France.
Macro M Hematologie Clinique, IHBN-CHU CAEN (University Hospital), Caen, France.
Lambrecht I Rheumatology Department, Maison Blanche Hospital, Reims University Hospitals, Reims, France.
Cliquennois M Unite d'Hematologie clinique, Groupement des hôpitaux de l'Institut Catholique (GHICL), Universite Catholique de Lille, Lille, France.
Vincent L Departement d'hematologie clinique, CHU de Montpellier, Montpellier, France.
Helias P Service d'Oncologie medicale, CHU de La Guadeloupe, Pointe-a-Pitre, Guadeloupe.
Avet-Loiseau H Laboratory for Genomics in Myeloma, Institut Universitaire du Cancer and University Hospital, Centre de Recherche en Cancerologie de Toulouse, Toulouse, France.
Moreno V CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Reis RM Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Varkonyi J 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
Kruszewski M Department of Hematology, University Hospital, Bydgoszcz, Poland.
Vangsted AJ Department of Haematology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.
Jurczyszyn A Jagiellonian University Medical College, Department of Hematology, Cracow, Poland.
Zaucha JM Gdynia Oncology Center, Gdynia and Department of Oncological Propedeutics, Medical University of Gdańsk, Gdańsk, Poland.
Sainz J Genomic Oncology Area, GENYO. Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.
Krawczyk-Kulis M Department of Bone Marrow Transplantation and Hematology-Oncology M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Gliwice Branch, Gliwice, Poland.
Wątek M Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Pelosini M Department of Oncology, Transplants and Advanced Technologies, Section of Hematology, Pisa University Hospital, Pisa, Italy.
Iskierka-Jażdżewska E Department of Hematology, Medical University of Lodz, Łódź, Poland.
Grząśko N Department of Experimental Hemato-oncology, Medical University of Lubli, Poland; Department of Hematology, St. John's Cancer Centre, Polish Myeloma Study Group, Lublin, Poland.
Martinez-Lopez J Hematology Department, Hospital 12 de Octubre, Universidad Complutense; CNIO, Madrid, Spain.
Jerez A Hematology and Medical Oncology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain.
Campa D Department of Biology, University of Pisa, Pisa, Italy.
Buda G Holycross Cancer Center of Kielce, Hematology Clinic, Kielce, Poland.
Lesueur F Inserm U900, Institut Curie, PSL Research University, Mines ParisTech, Paris, France.
Dudziński M Teaching Hospital No1, Hematology Dept, Rzeszow, Poland.
García-Sanz R Hematology Department, University Hospital of Salamanca, IBSAL, Salamanca, Spain.
Nagler A Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Rymko M Department of Hematology, Copernicus Hospital, Torun, Poland.
Jamroziak K Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Butrym A Wroclaw Medical University, Wroclaw, Poland.
Canzian F Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Obazee O Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Nilsson B Department of Laboratory Medicine, Division of Hematology and Transfusion medicine, Lund University, Lund, Sweden.
Klein RJ Department of Genetics and Genomic Sciences and Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Lipkin SM Medicine, Weill Cornell Medical College, New York, NY, USA.
McKay JD Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France. mckayj@iarc.fr.
Dumontet C ProfilExpert, Lyon, France. charles.dumontet@chu-lyon.fr.